Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases.
Antiphospholipid autoantibody
Antiphospholipid syndrome
Cardiovascular diseases
Rheumatic disease
Thrombosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
06 10 2023
06 10 2023
Historique:
received:
01
08
2023
accepted:
19
09
2023
medline:
1
11
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
β2-glycoprotein I (β2GPI) complexed with human leukocyte antigen DR (β2GPI/HLA-DR) was found to be a major autoantibody target in antiphospholipid syndrome (APS). This study aimed to reveal the association between anti-β2GPI/HLA-DR antibodies and vascular thromboses in women with systemic rheumatic diseases. We conducted a retrospective longitudinal study. We measured anti-β2GPI/HLA-DR antibodies and compared them with anti-phospholipid antibody (aPL) profiles and the adjusted global antiphospholipid syndrome score (aGAPSS). Using receiver operating characteristic (ROC) analysis, we determined the best cut-off value for arterial thrombosis. We also evaluated the validity of anti-β2GPI/HLA-DR antibodies by adding to conventional cardiovascular risk factors in multivariate logistic analysis. We evaluated 704 patients, including 66 (obstetric or thrombotic) APS, 13 primary APS, and 78 asymptomatic aPL carriers. Seventy-seven patients had a history of arterial thrombosis, and 14 patients had both arterial and venous thrombosis. These 14 patients, as well as patients with aGAPSS > 10 or triple-positive aPL profiles, displayed high anti-β2GPI/HLA-DR antibody titers. The ROC curve showed a sensitivity, specificity, and area under the curve (AUC) for arterial thrombosis of 33.8%, 91.4%, and 0.6009, respectively, with a cut-off value of 172.359 U/mL. The anti-β2GPI/HLA-DR antibody positivity using this cut-off value yielded an odds ratio of 5.13 (95%CI: 2.85-9.24), significantly improving the AUC from 0.677 to 0.730. Anti-β2GPI/HLA-DR antibodies are associated with arterial thrombosis in female patients with systemic rheumatic diseases.
Sections du résumé
BACKGROUND
β2-glycoprotein I (β2GPI) complexed with human leukocyte antigen DR (β2GPI/HLA-DR) was found to be a major autoantibody target in antiphospholipid syndrome (APS). This study aimed to reveal the association between anti-β2GPI/HLA-DR antibodies and vascular thromboses in women with systemic rheumatic diseases.
METHODS
We conducted a retrospective longitudinal study. We measured anti-β2GPI/HLA-DR antibodies and compared them with anti-phospholipid antibody (aPL) profiles and the adjusted global antiphospholipid syndrome score (aGAPSS). Using receiver operating characteristic (ROC) analysis, we determined the best cut-off value for arterial thrombosis. We also evaluated the validity of anti-β2GPI/HLA-DR antibodies by adding to conventional cardiovascular risk factors in multivariate logistic analysis.
RESULTS
We evaluated 704 patients, including 66 (obstetric or thrombotic) APS, 13 primary APS, and 78 asymptomatic aPL carriers. Seventy-seven patients had a history of arterial thrombosis, and 14 patients had both arterial and venous thrombosis. These 14 patients, as well as patients with aGAPSS > 10 or triple-positive aPL profiles, displayed high anti-β2GPI/HLA-DR antibody titers. The ROC curve showed a sensitivity, specificity, and area under the curve (AUC) for arterial thrombosis of 33.8%, 91.4%, and 0.6009, respectively, with a cut-off value of 172.359 U/mL. The anti-β2GPI/HLA-DR antibody positivity using this cut-off value yielded an odds ratio of 5.13 (95%CI: 2.85-9.24), significantly improving the AUC from 0.677 to 0.730.
CONCLUSION
Anti-β2GPI/HLA-DR antibodies are associated with arterial thrombosis in female patients with systemic rheumatic diseases.
Identifiants
pubmed: 37803443
doi: 10.1186/s13075-023-03175-8
pii: 10.1186/s13075-023-03175-8
pmc: PMC10557208
doi:
Substances chimiques
Autoantibodies
0
beta 2-Glycoprotein I
0
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Autoimmun Rev. 2013 Aug;12(10):1004-15
pubmed: 23541482
Rheumatology (Oxford). 2002 Aug;41(8):924-9
pubmed: 12154210
Expert Rev Clin Immunol. 2021 Apr;17(4):395-406
pubmed: 33686921
Front Immunol. 2019 Mar 15;10:487
pubmed: 30930907
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Blood. 2015 Apr 30;125(18):2835-44
pubmed: 25733579
Ann Rheum Dis. 2011 Nov;70(11):2029-36
pubmed: 21803750
Blood. 2011 Oct 27;118(17):4714-8
pubmed: 21765019
J Thromb Haemost. 2019 Jul;17(7):1134-1143
pubmed: 30864219
Lupus. 2012 Dec;21(14):1506-14
pubmed: 22936124
Arthritis Rheumatol. 2017 Jan;69(1):35-45
pubmed: 27785888
Blood. 2005 Feb 15;105(4):1540-5
pubmed: 15507529
J Exp Med. 1983 Apr 1;157(4):1339-53
pubmed: 6403654
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4
pubmed: 2349221
Arthritis Res Ther. 2022 Jun 11;24(1):140
pubmed: 35690831
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Int J Mol Sci. 2021 Mar 04;22(5):
pubmed: 33806694
Autoimmunity. 1992;13(2):95-9
pubmed: 1467439
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Circulation. 2007 Feb 20;115(7):928-35
pubmed: 17309939
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
Rheumatology (Oxford). 2023 Jun 12;:
pubmed: 37307082
Ann Rheum Dis. 2022 Jun;81(6):768-779
pubmed: 35110331
Int J Cardiol. 2017 Aug 1;240:72-77
pubmed: 28385357
Arthritis Rheum. 2012 Feb;64(2):504-12
pubmed: 21953404
Sci Rep. 2022 Jun 15;12(1):9916
pubmed: 35705662
Ann Rheum Dis. 2011 Jun;70(6):1083-6
pubmed: 21285115
Arthritis Rheum. 2011 Dec;63(12):3960-8
pubmed: 21898342
Clin Exp Rheumatol. 1998 Jul-Aug;16(4):423-7
pubmed: 9706422
J Thromb Haemost. 2020 Nov;18(11):2828-2839
pubmed: 33462974
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4917-21
pubmed: 6431411
Rheumatology (Oxford). 2023 Apr 3;62(4):1576-1585
pubmed: 35997555
Arthritis Rheum. 2002 Apr;46(4):1019-27
pubmed: 11953980
J Thromb Haemost. 2010 Jul;8(7):1540-6
pubmed: 20345724
Br J Dermatol. 2018 Jan;178(1):272-275
pubmed: 28403571
Sci Rep. 2021 Dec 7;11(1):23529
pubmed: 34876633
J Thromb Haemost. 2014 Dec;12(12):2034-7
pubmed: 25244443
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Front Immunol. 2022 Jul 29;13:930087
pubmed: 35967319
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3787-92
pubmed: 24567378
Rheumatology (Oxford). 2018 Apr 1;57(4):661-665
pubmed: 29342292
Blood. 2010 Aug 26;116(8):1336-43
pubmed: 20462962
Mod Rheumatol. 2021 Jan;31(1):29-33
pubmed: 31903831
Arthritis Rheumatol. 2020 Nov;72(11):1882-1891
pubmed: 32583563
Int Immunol. 2013 Apr;25(4):235-46
pubmed: 23334921
Lupus. 2014 Dec;23(14):1468-76
pubmed: 25164304
Int J Mol Sci. 2023 Jun 30;24(13):
pubmed: 37446134
Ann Rheum Dis. 2003 Nov;62(11):1071-7
pubmed: 14583570
Clin Exp Immunol. 1999 Jan;115(1):214-9
pubmed: 9933445
J Autoimmun. 2022 Apr;128:102813
pubmed: 35247655
Arthritis Rheum. 2005 Sep;52(9):2774-82
pubmed: 16142761
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Stroke. 2017 Mar;48(3):740-746
pubmed: 28108619
Biochem Biophys Res Commun. 2019 Apr 23;512(1):72-78
pubmed: 30871774
Atherosclerosis. 2018 Nov;278:60-65
pubmed: 30253290